Andrew Young
Chief Scientific & Medical Officer I2O Therapeutics
Seminars
Wednesday 2nd December 2026
From Pancreatic Amyloid to Therapeutic Hormone: Lessons from the Discovery & Development of Amylin
9:00 am
- Trace the evolution of amylin from its discovery within pancreatic amyloid deposits to recognition as a co-secreted metabolic hormone, revealing how changing biological understanding transformed an apparent marker of disease into a viable therapeutic target
- Review the foundational pharmacology that established amylin’s roles in satiety, gastric emptying, glucagon regulation and nutrient control, highlighting the experiments and translational decisions that enabled development of the first amylinmimetic medicines
- Reflect on the scientific and development lessons from Amylin Pharmaceuticals, including receptor uncertainty, peptide stability and formulation challenges, to identify what today’s developers should retain, or reconsider, when engineering the next generation of amylin therapeutics
